3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lung Neoplasms
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Pheochromocytoma
1
Paraganglioma
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Ductal Adenocarcinoma
1
Osteoradionecrosis
1
Mouth Neoplasms
1
Melanoma
1
Hereditary leiomyomatosis and renal cell cancer
1
Gliosarcoma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Craniopharyngioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Bevacizumab
35
durvalumab
23
atezolizumab
22
lenvatinib
20
Nivolumab
20
tremelimumab
16
Specimen Handling
14
Magnetic Resonance Spectroscopy
12
sintilimab
11
pembrolizumab
9
Ipilimumab
9
Sorafenib
8
tislelizumab
7
cabozantinib
5
X-Rays
5
Immunoglobulin G
5
Disulfides
5
Cyclophosphamide
5
regorafenib
4
Radiotherapy
4
Radiosurgery
4
Radiation
4
Oxaliplatin
4
Immunotherapy
4
Ethiodized Oil
4
fludarabine
3
donafenib
3
Surgical Procedures, Operative
3
Folfox protocol
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Contrast Media
×
90 days
×
Clear all
No trials found.